Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.
Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.
James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the ability to treat patients.
